Morphological changes in the temporomandibular joints in women with fibromyalgia and myofascial pain: A case series

Pharmacological treatments of fibromyalgia in adults; overview of phase IV clinical trials

Background: Fibromyalgia is a chronic neurological condition characterized by widespread pain. The effectiveness of current pharmacological treatments is limited. However, several medications have been approved for phase IV trials in order to evaluate them.

Aim: To identify and provide details of drugs that have been tested in completed phase IV clinical trials for fibromyalgia management in adults, including the primary endpoints and treatment outcomes. This article was submitted to Neuropharmacology, a section of the journal Frontiers in Pharmacology.

Method: Publicly available and relevant phase IV trials registered at ClinicalTrials.gov were analyzed. The uses of the trialed drugs for fibromyalgia were reviewed.

Results: As of 8 August 2022, a total of 1,263 phase IV clinical trials were identified, of which 121 were related to fibromyalgia. From these, 10 clinical trials met the inclusion criteria for the current study. The drugs used in phase IV trials are milnacipran, duloxetine, pregabalin, a combination of tramadol and acetaminophen, and armodafinil. The effectiveness of the current pharmacological treatments is apparently limited.

Conclusion: Due to its complexity and association with other functional pain syndromes, treatment options for fibromyalgia only are limited and they are designed to alleviate the symptoms rather than to alter the pathological pathway of the condition itself. Pain management specialists have numerous pharmacologic options available for the management of fibromyalgia.

Temporomandibular Disk Dislocation Impacts the Stomatognathic System: Comparative Study Based on Biexponential Quantitative T2 Maps

In this study, we aimed to assess the potential impact of temporomandibular disk displacement on anatomical structures of the stomatognathic system using biexponential T2 magnetic resonance imaging (MRI) maps. Fifty separate MRI scans of the temporomandibular joints (TMJ) of 25 patients were acquired with eight echo times. Biexponential T2 maps were created by weighted reconstruction based on Powell's conjugate direction method and divided into two groups: the TMJ without (32 images) and with (18 images) disk displacement. The disk, retrodiscal tissue, condylar bone marrow, masseter muscle, lateral and medial pterygoid muscles and dental pulp of the first and second molars were manually segmented twice. The intrarater reliability was assessed. The averages and standard deviations of the T2 times and fractions of each segmented region for each group were calculated and analysed with multiple Student's t-tests. Significant differences between groups were observed in the retrodiscal tissue, medial pterygoid muscle and bone marrow. The pulp short T2 component showed a trend toward statistical significance. The segmentation reliability was excellent (93.6%). The relationship between disk displacement and quantitative MRI features of stomatognathic structures can be useful in the combined treatment of articular disk displacement, pterygoid muscle tension and occlusive reconstruction.

Oxytocin inhibits hindpaw hyperalgesia induced by orofacial inflammation combined with stress

Oxytocin (OT) is recognized as a critical neuropeptide in pain-related disorders. Chronic pain caused by the comorbidity of temporomandibular disorder (TMD) and fibromyalgia syndrome (FMS) is common, but whether OT plays an analgesic role in the comorbidity of TMD and FMS is unknown. Female rats with masseter muscle inflammation combined with 3-day forced swim (FS) stress developed somatic hypersensitivity, which modeled the comorbidity of TMD and FMS. Using this model, the effects of spinal OT administration on mechanical allodynia and thermal hyperalgesia in hindpaws were examined. Furthermore, the protein levels of OT receptors and 5-HT2A receptors in the L4-L5 spinal dorsal horn were analyzed by Western blot. The OT receptor antagonist atosiban and 5-HT2A receptor antagonist ritanserin were intrathecally injected prior to OT injection in the separate groups. Intrathecal injection of 0.125 μg and 0.5 μg OT attenuated the hindpaw hyperalgesia. The expression of OT receptors and 5-HT2A receptors in the L4-L5 spinal dorsal horn significantly increased following intrathecal injection of 0.5 μg OT. Intrathecal administration of either the OT receptor antagonist atosiban or 5-HT2A receptor antagonist ritanserin blocked the analgesic effect of OT. These results suggest that OT may inhibit hindpaw hyperalgesia evoked by orofacial inflammation combined with stress through OT receptors and/or 5-HT2A receptors, thus providing a therapeutic prospect for drugs targeting the OT system and for patients with comorbidity of TMD and FMS.